Eugia Methylprednisolone Injectable Suspension Recall: Failed Dissolution Specifications
Eugia US LLC recalls 400mg per 5mL Methylprednisolone acetate Injectable Suspension due to failed dissolution specifications. This medication is for prescription use only and was manufactured in India. Consumers should contact the manufacturer for details.
Recall notice
Failed Dissolution Specifications
Contact the company
What happened, in plain English
Eugia US LLC is recalling a specific prescription medication because it failed dissolution tests. This means the medication may not work properly when injected, which could affect treatment effectiveness. The recall applies to certain lots manufactured in India. Read more at govinfonow.com/recall/32806-eugia-methylprednisolone-injectable-suspension-recall-failed-dissolution-specifications.
Source Summary by GovInfoNow · govinfonow.com/recall/32806-eugia-methylprednisolone-injectable-suspension-recall-failed-dissolution-specifications · Updated August 17, 2026 · FDA enforcement record: FDA #D-0366-2024
Cite this page
“Eugia Methylprednisolone Injectable Suspension Recall: Failed Dissolution Specifications.” GovInfoNow, updated August 17, 2026. https://govinfonow.com/recall/32806-eugia-methylprednisolone-injectable-suspension-recall-failed-dissolution-specifications. Based on FDA recall #D-0366-2024 (https://api.fda.gov/drug/enforcement.json?search=recall_number:%22D-0366-2024%22&limit=1).
Why it’s dangerous
The medication failed dissolution specifications, meaning it may not release the active ingredient properly when injected. This could lead to ineffective treatment if the medication does not work as intended. However, the recall does not specify a risk of injury or harm to the patient.
Who’s affected
Prescription patients using the recalled Methylprednisolone acetate Injectable Suspension. Those with the specific lot numbers (3MA23001-3MA23003) and expiration date 3/31/2025 are most at risk.
How to tell if you have this one
Check the product label for the lot numbers 3MA23001, 3MA23002, or 3MA23003. The expiration date is 3/31/2025. This medication is a prescription-only injectable suspension.
- Brand
Eugia- Category
Drug
What to do — step by step
Check Product Label
Look for lot numbers 3MA23001, 3MA23002, or 3MA23003 on the vial.
Where it went and when
Where it was distributed
Distributed in 4 states.
FDA distribution: “OH, TN, LA, MS” States read from FDA’s own wording; “not listed” means the notice does not name it.
States: Louisiana, Mississippi, Ohio, Tennessee.
Recall timeline
FDA published this recall 22 days after the firm started it.
- Firm started the recall
- FDA classified it Class II
- Published in FDA’s Enforcement Report
Dates from the agency record only; steps without a date are left out.
Similar recalls
Latest drug recalls
Keep exploring
Where this comes from
The facts (hazard, remedy, dates, manufacturer) are pulled from the official FDA recall record. The plain-language summary and step-by-step checklist are written by GovInfoNow to make the official notice easier to act on — they don’t replace it.
- Official source: FDA Recall #D-0366-2024 (February 20, 2024) — FDA publishes no per-recall page; this is the official machine-readable enforcement record. Search FDA recalls for D-0366-2024 to see it in context.
- Plain-language summary written by qwen3:4b on August 17, 2026, from the official record above. Not reviewed by a person — if it conflicts with the FDA notice, the notice is correct. Report an error on this page.
- GovInfoNow is an independent service and is not a government agency. We republish official FDA recall data; we don’t issue, amend or administer recalls.